Citations

Clear

7 citation(s) found for "Mendoza, Maria Alejandra".

Clinical characteristics and outcomes of invasive Listeria monocytogenes infection: a 45-year retrospective study at a U.S. Tertiary Center
Samreen, Ayesha , Dominguez, Maria Alejandra Mendoza, Vaillant, James J. , Saleh, Omar Abu , Abu Saleh, Omar , Samreen, Ayesha

Mayo Clinic

Open Forum Infectious Diseases | August 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ofid/ofag496 | PMID 42763558 Get It

Abstract Background Invasive listeriosis remains a leading cause of foodborne infection–related mortality in the United States and is associated with substantial case fatality despite appropriate antimicrobial therapy. Owing to the relative rarity of invasive disease, contemporary data evaluating clinical characteristics, optimal antimicrobial strategies, and predictors of mortality remain limited. Methods We conducted a retrospective cohort study of adults with laboratory-confirmed invasive Listeria monocytogenes infection at Mayo Clinic Health System sites from 1980 to 2024. Clinical syndromes were categorized into four mutually exclusive categories, namely bloodstream infection, central nervous system infection, pregnancy-associated infection, and other focal infections. The primary outcome was 1-year all-cause mortality. Secondary outcomes included 90-day mortality and residual neurological deficits among patients with neurolisteriosis. Results Fifty patients were included (median age, 72 years; 56% immunocompromised). The most common clinical presentations were bacteremia (44%) and neurolisteriosis (36%), followed by endovascular infection (12%) and peritonitis (6%). Most patients received a beta-lactam–based regimen, 46% aminopenicillin monotherapy, and 30% received combination therapy with gentamicin. Thirty-day, 90-day, and 1-year mortality were 10%, 12%, and 20%, respectively. Immunocompromised status and intensive care unit admission were associated with an increased risk of 1-year mortality, whereas adjunctive gentamicin therapy was not associated with improved survival. Conclusion Invasive listeriosis is associated with substantial morbidity and mortality, particularly among immunocompromised hosts. Host factors and severity of illness at presentation appear to be key drivers of unfavorable outcomes. Larger multicenter studies are needed to define optimal management strategies.
Unveiling the Unforeseen
Mendoza, Maria A. , Fugate, Jennifer E. , Kukla, Aleksandra , Razonable, Raymund R. , Chesdachai, Supavit , Mendoza, Maria Alejandra , Razonable, Raymund R , Chesdachai, Supavit

Mayo Clinic

New England Journal of Medicine | March 5, 2025 | Volume: 392 | Issue: 10 | Pages: 1018-1024

10.1056/nejmcps2401298 | PMID 40043240 Get It

Which allogeneic hematopoietic cell transplant recipients have an increased risk for delayed‐onset clinically significant cytomegalovirus infection after letermovir prophylaxis?
Mendoza, Maria A. , Bhaimia, Eric , Razonable, Raymund R. , Thoendel, Matthew , Mendoza, Maria Alejandra , Razonable, Raymund R , Alkhateeb, Hassan B.

Mayo Clinic

Transplant Infectious Disease | September 28, 2024 | Volume: 26 | Issue: 6 | Pages: No page available

10.1111/tid.14377 | PMID 39340371 Get It

AbstractIntroductionCytomegalovirus (CMV) reactivation is one of the most common complications after allogeneic hematopoietic stem cell transplantation (HSCT). Letermovir is approved for CMV prophylaxis among high‐risk recipients. However, delayed‐onset post‐prophylaxis clinically significant CMV infection (csCMVi) has been observed, suggesting the potential for extending letermovir prophylaxis beyond the first one hundred days post‐HSCT.MethodsRetrospective multicenter cohort study of allogeneic HSCT patients from August 2018 to March 2023. The primary aim of this study was to identify the risk factors at day 100 associated with delayed onset csCMVi, in patients who received letermovir prophylaxis up to day 100. Competing risk analysis was used to evaluate incidence with specific risk factors, using Gray's Test comparing groups for each event.ResultsAmong 166 eligible allogeneic HSCT recipients, the most common primary hematological diagnosis was acute myelogenous leukemia (AML) (42.2%). Twenty‐six (15.7%) developed a breakthrough csCMVi. Delayed‐onset csCMVi occurred in 23.5%, at a median time of 133 days after SCT. On multivariate analysis, having a matched unrelated donor (odds ratio [OR] 2.46) and a CMV donor negative/recipient positive status (OR 3.47) were associated with delayed onset csCMVi. In contrast, AML had a lower odd of having delayed‐onset csCMVi (OR 0.23).ConclusionsHaving a matched unrelated donor, a CMV donor negative/recipient positive status, and a non‐AML underlying disease were associated with delayed onset csCMVi. Prospective studies are needed to evaluate whether extended letermovir prophylaxis is beneficial for these patients. image
Rhodococcus infection: a 10-year retrospective analysis of clinical experience and antimicrobial susceptibility profile
Ranganath, Nischal , Kind, Dalton R., Wengenack, Nancy L. , Shah, Aditya , Mendoza, Maria Alejandra , Stevens, Ryan, Kind, Dalton, Wengenack, Nancy L , Ranganath, Nischal , Mendoza, Maria A. , Stevens, Ryan W.

Mayo Clinic

Journal of Clinical Microbiology | February 13, 2024 | Volume: 62 | Issue: 3 | Pages: No page available

10.1128/jcm.01537-23 | PMID 38349145 Get It

ABSTRACT Rhodococcus equi is an opportunistic pathogen known to cause pulmonary and extrapulmonary disease among immunocompromised patients. Treatment is frequently challenging due to intrinsic resistance to multiple antibiotic classes. While non- equi Rhodococcus spp. are prevalent, their clinical significance is poorly defined. There is also limited data on antibiotic susceptibility testing (AST) of Rhodococcus infection in humans. We conducted a single-center, retrospective cohort study evaluating clinical characteristics, microbiologic profile, and AST of Rhodococcus infections between June 2012 and 2022 at our tertiary academic medical center. Identification of Rhodococcus spp. was performed by Sanger 16S rRNA gene sequencing and/or matrix-assisted laser desorption ionization-time of flight mass spectrometry, and AST was performed by agar dilution. Three hundred twenty-two isolates of Rhodococcus spp. were identified from blood (50%), pulmonary (26%), and bone/joint (12%) sources. R. equi/hoagii, R. corynebacterioides , and R. erythropolis were the most frequently isolated species, with 19% of isolates identified only to genus level. One hundred ninety-nine isolates evaluated for AST demonstrated high-level resistance to amoxicillin/clavulanate, cephalosporins, and aminoglycosides. More than 95% susceptibility to imipenem, vancomycin, linezolid, rifampin, and clarithromycin was observed. Non- equi species showed a significantly more favorable AST profile relative to R. equi . Clinically significant Rhodococcus infection was rare with 10 cases diagnosed (majority due to R. equi ) and managed. The majority of patients received 2- or 3-drug combination therapy for 2–6 months, with favorable clinical response. Significant differences in AST were observed between R. equi and non- equi species. Despite high antimicrobial resistance to several antibiotic classes, imipenem and vancomycin remain appropriate empiric treatment options for R. equi . Future research evaluating mechanisms underlying antimicrobial resistance is warranted.
Left Ventricular Assist Device: Review of Antimicrobial Prophylaxis Strategies and Incidence of Infections at a Tertiary Care Center 12-Year Experience
Mendoza, Maria A. , Ranganath, Nischal , Garcia, Bismarck Bisono, Lahr, Brian D. , Stulak, John M., Shah, Aditya , Bisono, Bismarck , Mendoza, Maria Alejandra , Lahr, Brian , O'horo, John, Shah, Aditya S , Ranganath, Nischal , Bisono Garcia, Bismarck , Stevens, Ryan W. , O’Horo, John C.

Mayo Clinic

Open Forum Infectious Diseases | September 8, 2023 | Volume: 10 | Issue: 9 | Pages: No page available

10.1093/ofid/ofad465 | PMID 37732167 Get It

Abstract Background Left ventricular assist devices (LVAD) have an associated infection rate of 13%–80% postimplant. An optimal strategy for surgical infection prophylaxis (SIP) at the time of implantation has not been well defined. We aimed to evaluate the different LVAD implantation antibiotic prophylaxis regimens as well as the incidence of LVAD infection at our institution. Methods We performed a single-center, retrospective study of patients who underwent LVAD implantation between February 2007 and June 2019. The primary outcome was the incidence of LVAD infection (LVADI), within 3 months and 1 year of placement, between patients who received expanded or narrow-spectrum regimens for SIP. We assessed outcomes using Kaplan-Meier, time-to-first event. We used a noninferiority analysis, which was established if the narrow-spectrum event rate was no more than 5% greater than the expanded-spectrum event rate. Results We included 399 patients, 305 (76.4%) patients received narrow-spectrum SIP, whereas the remaining 94 (23.6%) patients received the expanded-spectrum regimen. Statistical noninferiority of the narrow spectrum to the multiple drug regimen was demonstrated at both time points, and statistical superiority of the narrow-spectrum group across 12-month follow up was further evident (P = .037). Conclusions We report evidence supporting noninferiority, or even superiority, of the narrow-spectrum over expanded-spectrum antimicrobial prophylaxis strategy with respect to LVADI. These findings support data-driven antimicrobial prophylaxis strategies.
Powassan Virus Encephalitis: A Tertiary Center Experience
Mendoza, Maria A. , Hass, Reece, Vaillant, James J. , Theel, Elitza S. , Toledano, Michel , Saleh, Omar Abu , Mendoza, Maria Alejandra , Vaillant, James, Abu Saleh, Omar , Johnson, Derek R.

Mayo Clinic

Clinical Infectious Diseases | August 3, 2023 | Volume: 78 | Issue: 1 | Pages: 80-89

10.1093/cid/ciad454 | PMID 37540989 Get It

Abstract Background Powassan virus (POWV) is an emerging arthropod-borne flavivirus, transmitted by Ixodes spp. ticks, which has been associated with neuroinvasive disease and poor outcomes. Methods A retrospective study was conducted at Mayo Clinic from 2013 to 2022. We included clinical and epidemiologic data of probable and confirmed neuroinvasive POWV cases. Results Sixteen patients with neuroinvasive POWV were identified; their median age was 63.2 years, and 62.5% were male. Six patients presented with rhombencephalitis, 4 with isolated meningitis, 3 with meningoencephalitis, 2 with meningoencephalomyelitis, and 1 with opsoclonus myoclonus syndrome. A median time of 18 days was observed between symptom onset and diagnosis. Cerebrospinal fluid analysis showed lymphocytic pleocytosis with elevated protein and normal glucose in the majority of patients. Death occurred within 90 days in 3 patients (18.8%), and residual neurologic deficits were seen in 8 survivors (72.7%). Conclusions To our knowledge, this is the largest case series of patients with neuroinvasive POWV infection. We highlight the importance of a high clinical suspicion among patients who live in or travel to high-risk areas during the spring to fall months. Our data show high morbidity and mortality rates among patients with neuroinvasive disease.
Effect of Rifabutin in Dolutegravir Dosing: A Case Series
Mendoza, Maria A. , Roldan, Giovanni A. , Castro, José G. , Ashkin, David , Peloquin, Charles A. , Boulanger, Catherine, Boulanger, Catherine V, Mendoza, Maria Alejandra , Peloquin, Charles A , Al‐Shaer, Mohammad H.

Mayo Clinic

Journal of the International Association of Providers of AIDS Care (JIAPAC) | August 26, 2022 | Volume: 21 | Issue: No issue available | Pages: No page available

10.1177/23259582221111077 | PMID 36026587 Get It

Background: Tuberculosis (TB) is the leading cause of death in human immunodeficiency virus (HIV)-infected people worldwide. Currently there are no studies examining the use of Rifabutin (RBN) and Dolutegravir (DTG) in co-infected persons. This is a case series of 4 co-infected patients receiving both agents who underwent Pharmacokinetic (PK) analysis. Methods and Results: This is a retrospective chart review study of four patients diagnosed with both HIV and TB, receiving RBN and DTG and undergoing therapeutic drug monitoring. All 4 cases had lower than expected DTG concentrations at least once, including those on the current recommended dose of DTG with RBN, and even those receiving higher doses. Conclusions: Given the frequency of low DTG and RBN concentrations, therapeutic drug monitoring (TDM) for these drugs is advisable. Prospective clinical studies are needed to further determine the PK interactions between RBN and DTG, and virologic response to treatment.